YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Adeno Associated Virus Vector Manufacturing Market size & share revenue was valued at…
EQT is facing heightened attention after parents sued its subsidiaries over alleged health impacts from emissions and regulators cited the company for an “abandoned” shale well in Pennsylvania, while it also approaches a deadline on a pote…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Oxford Biomedica is in “preliminary discussions” about selling out to the private…
As the European market begins 2026 on a positive note, the pan-European STOXX Europe 600 Index has climbed by 2.27%, buoyed by optimism surrounding the economy, company earnings, and a supportive interest rate environment. With major stock…
OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating. The acquisition expands OXB’s viral vector manufacturing capa…
In recent weeks, European markets have shown resilience with the pan-European STOXX Europe 600 Index climbing by 1.40%, buoyed by hopes of lower U.S. borrowing costs and a rebound in eurozone business activity. As investors navigate these…
In recent days, the UK market has faced challenges as the FTSE 100 index slipped due to weak trade data from China, highlighting concerns about global economic recovery and its impact on commodity-linked companies. Despite these pressures,…
The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting global economic interdependencies. In such a climate, identifying high-growth tech st…
OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 April, OXB US exercised its call option on 1…
Oxford BioMedica plc Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK…
Oxford BioMedica plc Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and…
As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of Oxford Biomedica plc (LON:OXB), who have seen the share price tank a massive 79% over a t…
Oxford BioMedica plc Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing) On track to achieve 202…
Oxford BioMedica plc Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Méri…
Insiders who bought UK£396.0k worth of Oxford Biomedica plc's (LON:OXB) stock at an average buy price of UK£2.98 over the last year may be disappointed by the recent 14% decrease in the stock. Insiders buy with the expectation to see their…
One thing we could say about the analysts on Oxford Biomedica plc (LON:OXB) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue and earnings per share…
Oxford Biomedica (LON:OXB) First Half 2023 Results Key Financial Results Revenue: UK£43.1m (down 33% from 1H 2022). Net loss: UK£48.0m (loss widened by 88% from 1H 2022). UK£0.50 loss per share (further deteriorated from UK£0.27 loss in 1H…
The non-exclusive, multi-year license and supply agreement enables use of LentiVector® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing goals EMERYVILLE, Calif., Sept. 20, 2023 /…
Oxford BioMedica plc The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue o…
Oxford BioMedica plc Oxford Biomedica to host webinar showcasingthe TetraVectaTMsystem Oxford, UK – 7September2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today…
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. At this point some shareholders may be questioning their investment in Oxford…
Oxford BioMedica plc Oxford Biomedica launches TetraVectaTM - the next generation lentiviral vector system Oxford, UK – 15May2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vec…
With a price-to-sales (or "P/S") ratio of 2.9x Oxford Biomedica plc (LON:OXB) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United Kingdom have P/S ratios greater than 20.3x…
Oxford BioMedica plc Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26thApril2023:Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today…
Insiders who acquired UK£780k worth of Oxford Biomedica plc's (LON:OXB) stock at an average price of UK£5.03 in the past 12 months may be dismayed by the recent 10% price decline. Insiders invest with the hopes of seeing their money grow i…
Oxford BioMedica plc Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathiasbrings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly…
Oxford Biomedica plc (LON:OXB) shareholders should be happy to see the share price up 26% in the last quarter. But that doesn't change the fact that the returns over the last year have been less than pleasing. In fact the stock is down 50%…
How far off is Oxford Biomedica plc (LON:OXB) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's…
Oxford BioMedica plc The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue o…
Oxford BioMedica plc Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell the…
Oxford BioMedica plc The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue o…
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Oxford Biomedica plc (LON:OXB), that sends out a positive message to the company's shareholders. W…
Half Year 2022 Oxford BioMedica PLC Earnings Call Oxford Sep 15, 2022 (Thomson StreetEvents) -- Edited Transcript of Oxford BioMedica PLC earnings conference call or presentation Thursday, September 15, 2022 at 12:00:00pm GMT TEXT version…
Oxford Biomedica has been hit by the lack of demand for COVID vaccines. Photo: Hannah Beier/Reuters Oxford Biomedica (OXB.L)reported a revenue loss in the first half of the year as demand for COVID vaccines slumps. The British biotech firm…
The nature of investing is that you win some, and you lose some. Anyone who held Oxford Biomedica plc (LON:OXB) over the last year knows what a loser feels like. In that relatively short period, the share price has plunged 66%. At least th…
Oxford BioMedica plc Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26July2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell…